Published On: Fri, Feb 21st, 2014

Healthcare Stocks Declarations – Antares Pharma (NASDAQ:ATRS), Onconova Therapeutics (NASDAQ:ONTX), Raptor Pharmaceutical (NASDAQ:RPTP), Actavis (NYSE:ACT)

Antares Pharma Inc (NASDAQ:ATRS) [Trend Analysis] shares trading performance in last session was noticeable, stocks increased by 3.41% with market capitalization of $618.92, as outstanding shares was $127.61M. Antares Pharma Inc. (ATRS) reported that its Vibex QuickShot treatment for low testosterone delivered positive results in a Phase 2 trial. President and Chief Executive Officer, Paul K. Wotton stated that they are very hopeful about the possible for a self-administered, once weekly subcutaneous dose of testosterone based on the outcome of this study.

The average analysts of Wall Street, predicts revenue of firm of $6.15M in latest quarter and on contradiction, professionals forecast $8.17M revenues for the upcoming quarter. Recently in a pool of analysts, 4 analysts rates its stocks at “strong buy,” 1 analysts rate it at “Buy.”

Acts and Reacts in Analytic Report, Finds (NASDAQ:ATRS)

Onconova Therapeutics Inc (NASDAQ:ONTX) [Trend Analysis] lost -36.58%, closing the day at $8.79. The firm has market capitalization of $188.20M, and enterprise value of $182.72M. The cancer-focused biopharmaceutical company Onconova Therapeutics Inc. (ONTX) reported that a late-stage clinical trial of its drug rigosertib failed to meet the primary endpoint. The examination had enrolled patients with higher risk myelodysplastic syndromes who had progressed on, failed, or declined after prior therapy with hypomethylating agents. The price over sales value of $51.23 for the most recent quarter. Corporation has the total of cash of $116.60M as compares to total debt of $0.00 for the most recent quarter.

Why Like Investors Show Confidence on (NASDAQ:ONTX)

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) [Trend Analysis] reported the gain of 14.88% and closed at $17.14 with the total traded volume of $7.14M shares. Raptor Pharmaceutical Corp. (RPTP) declared that its prospective Huntington’s disease treatment met primary endpoints in an ongoing Phase 2/3 clinical examination. The lead investigator for the clinical examination, Christophe Verny¬† stated that they are very encouraged by these examination results and they believe that the significant slowdown of loss of muscle control in these untimely stage patients indicates that RP103 is potentially effective at slowing the progression of Huntington’s disease.

Its market capitalization is $1.05B. The stock owned by the Financial Institutions was 48%. The company’s shares have gained +10.36% in the last one month and +39.79% in the previous three months, compared to an increase of +1.67% and +8.83% in the Nasdaq during the respective periods.

What are Prospects of (NASDAQ:RPTP), Find the Free Technical Analysis

Actavis plc (NYSE:ACT) [Trend Analysis] reported that it swung to a Q4 loss on restructuring-related costs and other items that masked strong double-digit revenue growth. Adjusted results beats anticipates. Shares trading performance in last session was noticeable, stocks surged 4.66% with market capitalization of $36.68 billion, as shares volume was 5.88 million. While plunged in afterhours trading of around 1%.

Why Intension Diverter List Finds (NYSE:ACT)

Disclaimer

This content does not and shall not represent an offer to sell or the solicitation of an offer to buy any of the company’s stocks or securities. As well nor shall there be any sale of the company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction. Read Full Disclaimer Here

The eMarkets Daily news department is not involved in the creation of this content. See More Here

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>